about
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrateChemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate in vivoAnticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapyImmunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy.Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.Positive impact of autophagy in human breast cancer cells on local immunosurveillance.NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy.Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy.Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer.Regulation of autophagy by cytosolic acetyl-coenzyme A.Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
P50
Q28553228-2570A120-C268-403B-B694-5F4384415E96Q30276247-D1CEB64C-4D4A-43E0-8D3C-7E8E9F6AFEB0Q30358552-FBE976E7-AD82-416B-AA29-DE57521FD761Q31144277-EFF07E44-100B-4F48-95AB-9B4FB0699403Q34542239-992253A1-1EB1-43F8-B473-09BCCBDB9EFAQ35833921-1D565260-A0CE-41E0-8BE3-091119D6EA43Q36189455-A2494BFC-4E82-4E75-BA27-E4A011EB5AB9Q36293343-393A903B-ABEF-4E38-85DB-F0F92051B928Q36356176-AF64CD74-9BFC-43C3-87A0-F992E5323329Q36710945-E2C7BFCE-7465-4A49-AE51-879BF01CEB20Q36777278-2CBA48DF-E752-458B-987B-007C42A6FA6DQ36798051-E6A6B0B1-3696-4F6D-A82B-495D4F25DBCBQ36862687-DAF2679D-3789-4432-A153-000EEAAE0C07Q37079091-B0C78C3C-E8FB-4F4C-BBD3-E6F15285DA3DQ37558627-295E9346-273A-43E6-8BEC-7F8B42C7592BQ37616478-B7760294-A35A-44E4-9561-B2DE05DDF388Q37732220-6B4D4D79-C38E-48AE-ABAC-EAB1372D4C0DQ38823705-BD0C28EE-07E0-4375-9F64-0F87B69F8922Q38838547-812FDDD5-1AB0-4647-895D-B904BDB1638DQ38886708-488BF5C0-08C4-40A1-BC9E-73DB37CC3B2FQ38971333-D873B1BB-76A8-4C3B-963C-6AD7B826D0F4Q39021728-2891D58E-6610-46E8-AE59-B623C55A6E8FQ39255686-30BD9A64-76B5-4AAD-89B0-60053C06F27AQ40939669-63065067-AB1D-4701-ABC0-39A4CE936724Q41091286-7C3E8BEF-9BEF-421C-AEC3-4EBA57C04A84
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David P Enot
@ast
David P Enot
@en
David P Enot
@es
David P Enot
@sl
type
label
David P Enot
@ast
David P Enot
@en
David P Enot
@es
David P Enot
@sl
prefLabel
David P Enot
@ast
David P Enot
@en
David P Enot
@es
David P Enot
@sl
P106
P21
P31
P496
0000-0002-4290-509X